200 related articles for article (PubMed ID: 15640551)
1. Cdx2 as a marker for neuroendocrine tumors of unknown primary sites.
Erickson LA; Papouchado B; Dimashkieh H; Zhang S; Nakamura N; Lloyd RV
Endocr Pathol; 2004; 15(3):247-52. PubMed ID: 15640551
[TBL] [Abstract][Full Text] [Related]
2. Value of Islet 1 and PAX8 in identifying metastatic neuroendocrine tumors of pancreatic origin.
Koo J; Mertens RB; Mirocha JM; Wang HL; Dhall D
Mod Pathol; 2012 Jun; 25(6):893-901. PubMed ID: 22388755
[TBL] [Abstract][Full Text] [Related]
3. CDX2 may be a useful marker to distinguish primary ovarian carcinoid from gastrointestinal metastatic carcinoids to the ovary.
Desouki MM; Lioyd J; Xu H; Cao D; Barner R; Zhao C
Hum Pathol; 2013 Nov; 44(11):2536-41. PubMed ID: 24029704
[TBL] [Abstract][Full Text] [Related]
4. Expression of the intestinal transcription factor CDX2 in carcinoid tumors is a marker of midgut origin.
Jaffee IM; Rahmani M; Singhal MG; Younes M
Arch Pathol Lab Med; 2006 Oct; 130(10):1522-6. PubMed ID: 17090195
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of CDX-2 and TTF-1 expressions in separating metastatic neuroendocrine neoplasms of unknown origin.
Lin X; Saad RS; Luckasevic TM; Silverman JF; Liu Y
Appl Immunohistochem Mol Morphol; 2007 Dec; 15(4):407-14. PubMed ID: 18091383
[TBL] [Abstract][Full Text] [Related]
6. Islet 1 (Isl1) expression is a reliable marker for pancreatic endocrine tumors and their metastases.
Schmitt AM; Riniker F; Anlauf M; Schmid S; Soltermann A; Moch H; Heitz PU; Klöppel G; Komminoth P; Perren A
Am J Surg Pathol; 2008 Mar; 32(3):420-5. PubMed ID: 18300808
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic Utility of Orthopedia Homeobox (OTP) in Pulmonary Carcinoid Tumors.
Nonaka D; Papaxoinis G; Mansoor W
Am J Surg Pathol; 2016 Jun; 40(6):738-44. PubMed ID: 26927888
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors.
Srivastava A; Hornick JL
Am J Surg Pathol; 2009 Apr; 33(4):626-32. PubMed ID: 19065104
[TBL] [Abstract][Full Text] [Related]
9. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas.
Werling RW; Yaziji H; Bacchi CE; Gown AM
Am J Surg Pathol; 2003 Mar; 27(3):303-10. PubMed ID: 12604886
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical Characterization of the Origins of Metastatic Well-differentiated Neuroendocrine Tumors to the Liver.
Yang Z; Klimstra DS; Hruban RH; Tang LH
Am J Surg Pathol; 2017 Jul; 41(7):915-922. PubMed ID: 28498280
[TBL] [Abstract][Full Text] [Related]
11. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2.
Panarelli NC; Yantiss RK; Yeh MM; Liu Y; Chen YT
Am J Clin Pathol; 2012 Aug; 138(2):211-22. PubMed ID: 22904132
[TBL] [Abstract][Full Text] [Related]
12. Is CDX2 immunostaining useful for delineating anorectal from penile/vulvar squamous cancer in the setting of squamous cell carcinoma with clinically unknown primary site presenting with histologically confirmed inguinal lymph node metastasis?
Gunia S; Koch S; May M
J Clin Pathol; 2013 Feb; 66(2):109-12. PubMed ID: 23105122
[TBL] [Abstract][Full Text] [Related]
13. Fine needle aspiration diagnosis of neuroendocrine tumors in the liver.
Gupta RK; Naran S; Lallu S; Fauck R
Pathology; 2000 Feb; 32(1):16-20. PubMed ID: 10740799
[TBL] [Abstract][Full Text] [Related]
14. Primary ovarian carcinoid tumors may express CDX-2: a potential pitfall in distinction from metastatic intestinal carcinoid tumors involving the ovary.
Rabban JT; Lerwill MF; McCluggage WG; Grenert JP; Zaloudek CJ
Int J Gynecol Pathol; 2009 Jan; 28(1):41-8. PubMed ID: 19047909
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of CDX2 and TTF-1 in differentiating gastrointestinal from pulmonary carcinoids.
Saqi A; Alexis D; Remotti F; Bhagat G
Am J Clin Pathol; 2005 Mar; 123(3):394-404. PubMed ID: 15716236
[TBL] [Abstract][Full Text] [Related]
16. CDX2 is a useful marker of intestinal-type differentiation: a tissue microarray-based study of 629 tumors from various sites.
De Lott LB; Morrison C; Suster S; Cohn DE; Frankel WL
Arch Pathol Lab Med; 2005 Sep; 129(9):1100-5. PubMed ID: 16119980
[TBL] [Abstract][Full Text] [Related]
17. [Transcription factors: which diagnostic applications?].
Scoazec JY
Ann Pathol; 2012 Nov; 32(5 Suppl):S32-3. PubMed ID: 23127931
[No Abstract] [Full Text] [Related]
18. Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites.
Oliveira AM; Tazelaar HD; Myers JL; Erickson LA; Lloyd RV
Am J Surg Pathol; 2001 Jun; 25(6):815-9. PubMed ID: 11395561
[TBL] [Abstract][Full Text] [Related]
19. [Differential diagnostic value of the expression of the transcription factor PDX-1 in neuroendocrine and non-neuroendocrine tumors of the pancreas and other organs].
Gurevich LE; Proshchina AE; Voronkova IA; Ashevskaya VE; Korosteleva PA; Dolzhansky OV
Arkh Patol; 2019; 81(5):11-21. PubMed ID: 31626200
[TBL] [Abstract][Full Text] [Related]
20. Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices.
Rekhtman N; Desmeules P; Litvak AM; Pietanza MC; Santos-Zabala ML; Ni A; Montecalvo J; Chang JC; Beras A; Preeshagul IR; Sabari JK; Rudin CM; Ladanyi M; Klimstra DS; Travis WD; Lai WC
Mod Pathol; 2019 Jul; 32(8):1106-1122. PubMed ID: 30923345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]